Advertisement
Either agent is approximately two-fold more effective than 80 mg ofGFT505, an investigational agent currently in early phase II development.[5]
Published data show a potential role for fenofibrate in treatingnon-alcoholic fatty liver disease, significantly decreasing the proportion ofpatients with liver dysfunction.[1]
Advertisement
Fenofibrate significantly reduced both liver enzymes, alanine aminotransferase (ALT) and aspartate amino transferase (AST), unlike GFT505.[10]
Commenting on these data, these experts said: 'These new data show thatGFT505 is unlikely to have the potential to replace generic fenofibrate andbezafibrate in treating patients with atherogenic dyslipidemia.'
(Due to the length of the above URLs, it may be necessary to copy andpaste those hyperlinks into your Internet browser's URL address field. Removethe space if one exists.)Reviewing published evidence, these experts argued that: - Elevated triglycerides (>150 mg/dL) are decreased by 43% with generic fenofibrate[2] and 32% with generic bezafibrate[2] - Low HDL cholesterol (<40 mg/dL) is increased by 18%[3],[4]
SOURCE international experts
